脂肪酸β氧化FATP-CPI通路在心肌缺血诱导脂代谢紊乱中的作用及活血化瘀中药的干预机制研究

脂质浸润学说认为，脂质代谢紊乱是导致冠心病心肌缺血的重要病理机制，但前期采用2D-MS、GC-MS等组学技术对单纯冠心病心肌缺血血瘀证小型猪进行蛋白组与代谢组学研究发现，没有任何脂质干预、单纯的心肌缺血血瘀证模型反而出现了以血浆ApoA-I、LDL、β-羟丁酸等脂类分子变化为主要表现的脂类代谢紊乱。本项目拟借助单纯的冠心病心肌缺血模型，采用NMR、PCR技术，结合KEGG通路分析等生物信息学方法，进一步确认血浆脂质代谢紊乱的整体变化情况，探讨单纯心肌缺血导致脂代谢紊乱的关键病理环节。以心脏对脂肪酸的吸收与β氧化障碍FATP-CPI通路为主要切入点，确有疗效的中药复方丹七片进行缺血与脂质代谢紊乱因果关系的再验证，寻找出单纯缺血引发脂代谢紊乱的内在病理机制以及活血化瘀中药的干预环节，提出新的冠心病预防与治疗的环节，进一步深化对冠心病发病机制的认识，同时为其他缺血性疾病的防治提供新的研究思路。

Lipid infiltration theory believes that the disorder of lipid metabolism is important pathological mechanisms that lead to coronary heart disease (myocardial ischemia), but the early study on minitureswine with myaocardial ischemia of blood stasis syndrome based on 2D-MS, GC-MS -omics technology found that, without any lipid intervention, blood stasis syndrome model of myocardial ischemia appeared to the change of plasma ApoA-I, LDL, beta-hydroxybutyric acid and other lipid molecules as the main manifestation of lipid metabolism disorders. The project is planned with the application of animal model of myocardial ischemia with blood stasis syndrome, by using NMR, PCR combined with KEGG pathways analysis and bioinformatics methods to further confirm the overall changes of plasma lipid metabolism disorders, to investigate key pathological manchenism of the myocardial ischemia causing lipid metabolic disorders. Ischemia and lipid metabolism disorders relationship are researched by investigating cardiac fatty acid uptake and β-oxidation barriers especially FATP-CPI pathway as the main entry point, then after validated by the efficient Chinese herbal compound, to find out the intrinsic pathological mechanisms of ischemia causing lipid metabolism disorders and the mechanisms of promoting blood circulation therapy intervention. Our research is to clarify the of Coronary Heart disease with blood stasis syndrome,and discussing the intrinsic pathological mechanism of the prevention and treatment of Coronary Heart disease to further deepen our understanding of coronary heart disease pathogenesis. This will provide a new treatment strategy for other ischemia diseases.